mumbai dishman pharmaceuticals chemicals on monday said it will acquire the fine chemicals vitamin d and analogues business from the netherlandsbased solvay pharmaceuticals bv for an undisclosed amountthe company on monday informed the bombay stock exchange bse that it has entered into a memorandum of understanding mou with solvay pharmaceuticals for acquisition of the business unitas part of this deal all facilities people and activities located at solvays veenendaal site in the netherlands and technology patent and intellectual property rights for fine chemicals vitamin d and its analogues business would be transferred to the company after completion of due diligence procedures and other approvalsthe transfer of ownership would be completed during 2007 the statement addedthe intended sale of solvays unit is a result of the netherlandbased firms strategy to focus on the main therapeutic areas of cardiometabolic and neuroscience treatments and hive off the noncore businessdishman pharma has a preexisting longterm relationship with solvay for contract manufacturing of a patented api and intermediates acquiring the cholesterol vitamin d and its analogues business is a step in right direction it will not only increase products of dishman but also bring new customer relationships j r vyas the companys managing director saiddishman pharma would retain production of cholesterol and vitamin d analogues at veenendaal and transfer the vitamin d3 production to its indian plants the statement added